

What science can do

AstraZeneca 

AstraZeneca Development Pipeline as at 6 February 2025



Development Pipeline as at 6 February 2025


Key

 Partnered product

AstraZeneca-sponsored or -directed trial New Molecular Entities (NMEs) and significant indications

Anticipated data timing and submission status is provided for assets in Phase III or beyond. As disclosure of compound information is balanced by the business need to maintain confidentiality, information in relation to some compounds listed here has not been disclosed at this time.

Phase I

Compound	Mechanism	Additional Information	Area Under Investigation
Oncology			
AZD0022	KRas G12D inhibitor		solid tumours
AZD0120	autologous anti-CD19 and anti-BCMA CAR-T cell immunotherapy		multiple myeloma
AZD0305	GPRC5D ADC		relapsed/refractory multiple myeloma
AZD0486	CD19/CD3 next-generation bispecific T-cell engager		r/r B-cell non-Hodgkin lymphoma
AZD0486	CD19/CD3 next-generation bispecific T-cell engager		B-cell acute lymphoblastic leukaemia
AZD0754	STEAP2 CAR-T		prostate cancer
AZD1390	ATM inhibitor		glioblastoma
AZD2068	EGFR cMET radioconjugate		solid tumours
AZD3470	PRMT5 inhibitor		classic Hodgkin lymphoma, solid tumours
AZD5492	CD20 TITAN T-cell engager		haematology
AZD5851	GPC3 CAR-T		hepatocellular carcinoma
AZD5863	CLDN18.2 x CD3 bispecific antibody (HBM7022)		solid tumours
AZD6422	CLDN18.2 CAR-T		solid tumours
AZD7003 (China)	GPC3 CAR-T		hepatocellular carcinoma/squamous non-small cell lung cancer
AZD8421	CDK2 inhibitor		solid tumours
AZD9592	EGFR/cMET TOP1i ADC		solid tumours
AZD9829	CD123 TOP1i ADC		acute myeloid leukaemia, myelodysplastic syndromes
NT-112	TGFBR2 KO armored TCR-T targeting KRAS G12D		solid tumour
NT-125	autologous, fully-individualised, multi-specific TCR-T targeting neoantigens		solid tumours
NT-175	TGFBR2 KO armored TCR-T targeting TP53 R175H		solid tumours
volrustomig + lenvatinib	PD-1/CTLA-4 bispecific mAb + VEGF		advanced renal cell carcinoma
CVRM			
AZD0233	CX3CR1		dilated cardiomyopathy
AZD1705	lipid lowering		cardiovascular disease
AZD2373	podocyte health		nephropathy
AZD4144	inflammation modulator		cardiorenal disease
AZD9550	GLP-1R glucagon dual agonist		non-alcoholic steatohepatitis
Respiratory & Immunology			
AZD0120	autologous anti-CD19 and anti-BCMA CAR-T cell immunotherapy		systemic lupus erythematosus
AZD1163	bispecific antibody		rheumatoid arthritis
AZD6793	IRAK4 inhibitor		inflammatory diseases
AZD6912	siRNA		rheumatoid arthritis
AZD8965	inhibition of arginase enzyme		idiopathic pulmonary fibrosis
Vaccines and Immune Therapies			
AZD0292	pseudomonas Psl-PcrV bispecific mAb		non-CF bronchiectasis
AZD5148	anti-clostridioides difficile TcdB mAb		reduction of <i>C. diff</i> recurrence
AZD7760	mAb combination targeting S aureus virulence factors		prevention of Staph aureus infection
mRNA VLP vaccine	mRNA-VLP vaccine		prevention of COVID-19
Other Medicines			
MEDI1814	amyloid beta mAb		Alzheimer's disease
Rare Disease			
ALXN1920	kidney-targeted factor H fusion protein		nephrology
ALXN2030	siRNA targeting complement C3		nephrology
ALXN2080	oral factor D inhibitor		healthy volunteers

Phase II

Compound	Mechanism	Additional Information	Area Under Investigation
Oncology			
AZD0486 SOUNDTRACK-B	CD19/CD3 next-generation bispecific T-cell engager		B-cell non-Hodgkin lymphoma

Development Pipeline *continued*

Phase II *continued*

Compound	Mechanism	Additional Information	Area Under Investigation
AZD0901	CLDN18.2 MMAE ADC		solid tumours
AZD5335	anti-folate receptor alpha topoisomerase 1 inhibitor ADC		ovarian cancer, lung adenocarcinoma
AZD9574	PARP1 selective		advanced solid malignancies
camizestrant	selective estrogen receptor degrader		estrogen receptor +ve breast cancer
ceralaseritib	ATR inhibitor		solid tumours
FPI-2265	PSMA radioconjugate	PP	prostate cancer
IPH5201 + <i>Imfinzi</i>	CD39 + PD-L1	PP	neoadjuvant/adjuvant NSCLC
puxitatumig samrotecan (AZD8205)	B7-H4 targeting ADC		solid tumours
rilvegostomig ARTEMIDE-01	PD-1/TIGIT bispecific mAb	PP	solid tumours
saruparib	PARP1 selective		solid tumours
volrustomig	PD-1/CTLA-4 bispecific mAb		solid tumours
volrustomig eVOLVE-01	PD-1/CTLA-4 bispecific mAb		NSCLC
volrustomig eVOLVE-02	PD-1/CTLA-4 bispecific mAb		cervical cancer, head and neck squamous cell carcinoma
CVRM			
AZD0780	PCSK9		dyslipidaemia
AZD2389	anti-fibrotic mechanism		metabolic dysfunction-associated steatohepatitis
AZD2693	NASH resolution		non-alcoholic steatohepatitis
AZD3427	relaxin mimetic		heart failure
AZD5004	oral GLP-1 receptor agonist		T2D/chronic weight management
AZD5462	RXFP1 agonist	PP	heart failure
AZD6234	peptide		chronic weight management in overweight or obesity
balcinrenone/dapagliflozin	MR modulator + SGLT2 inhibitor	<i>Farxiga</i> in the US; <i>Forxiga</i> in rest of world	CKD
zibotentan/dapagliflozin	endothelin A receptor antagonist/SGLT2 inhibitor	dapagliflozin is marketed as <i>Farxiga</i> in the US; <i>Forxiga</i> in rest of world.	liver cirrhosis
Respiratory & Immunology			
atuliflapon	FLAP inhibitor		asthma
AZD4604	inhaled JAK1 inhibitor		asthma
AZD7798	humanised monoclonal antibody targets T-cells subset		Crohn's disease
AZD8630	inhaled TSLP FAb	PP	asthma
tozorakimab FRONTIER 3	IL-33 mAb		asthma
Vaccines and Immune Therapies			
IVX-A12	virus-like particle (VLP) vaccine	IVX-A12 is a virus-like particle combination vaccine for the prevention of lower respiratory tract disease (LRTD) caused RSV and hMPV.	RSV and human metapneumovirus (hMPV)
Other Medicines			
MEDI0618	PAR2 antagonist mAb		migraine
MEDI7352	NGF/TNF bispecific mAb		osteoarthritis pain and painful diabetic neuropathy
Rare Disease			
MEDI1341	alpha synuclein mAb	PP	multiple system atrophy/Parkinson's disease

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major markets)

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
Oncology				
AZD0486	CD19/CD3 next-generation bispecific		follicular lymphoma	>2026
SOUNDTRACK-F1	T-cell engager			
AZD0901	CLDN18.2 MMAE ADC		gastric 2L+	2026
CLARITY-Gastric01				
camizestrant + CDK4/6i	selective estrogen receptor degrader + CDK4/6 inhibitors		1st-line HR+ HER2- ESR1m breast cancer	H2 2025
SERENA-6				
camizestrant + palbociclib	selective estrogen receptor degrader + CDK4/6 inhibitor		1st-line HR+ HER2- breast cancer	2026
SERENA-4				
camizestrant	selective estrogen receptor degrader		HR+ HER2- extended adjuvant breast cancer	>2026
CAMBRIA-1				

Development Pipeline *continued*

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major markets) *continued*

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
camizestrant +/- abemaciclib CAMBRIA-2	selective estrogen receptor degrader + CDK4/6 inhibitor		ER+/HER2- early breast cancer	>2026
ceralasertib + <i>Imfinzi</i> LATIFY	ATR inhibitor + PDL-1 mAb		NSCLC	H2 2025
<i>Datroway</i> (datopotamab deruxtecan) TROPION-Breast01	TROP2 ADC	PP	2-3L HR+ HER2- breast cancer	Launched
<i>Imfinzi</i> + <i>Imjudo</i> HIMALAYA	PD-L1 mAb + CTLA-4 mAb		1st-line hepatocellular carcinoma	Launched
<i>Imfinzi</i> +/- oleclumab +/- monalizumab PACIFIC-9	PD-L1 + NKG2A or PD-L1 + CD73	PP	unresectable Stage III NSCLC	2026
rilvegostomig ARTEMIDE-Biliary01	PD-1/TIGIT bispecific mAb	PP	adjuvant biliary tract cancer	>2026
rilvegostomig ARTEMIDE-Lung02	PD-1/TIGIT bispecific mAb	PP	squamous NSCLC 1L	>2026
rilvegostomig ARTEMIDE-Lung03	PD-1/TIGIT bispecific mAb	PP	non-squamous NSCLC 1L	>2026
saruparib EvoPAR-Breast01	PARP1Sel		BRCA/PALB2m HR+ve metastatic breast cancer	>2026
saruparib EvoPAR-Prostate01	PARP1Sel		metastatic castration-sensitive prostate cancer	>2026
<i>Truqap</i> + <i>Faslodex</i> CAPitello-291	AKT inhibitor + fulvestrant		2nd-line and beyond in AI resistant locally advanced (inoperable) or metastatic breast cancer	Launched
volrustomig eVOLVE-Cervical	PD-1/CTLA-4 bispecific mAb		high-risk locally advanced cervical cancer	>2026
volrustomig eVOLVE-HNSCC	PD-1/CTLA-4 bispecific mAb		unresected locally advanced head and neck squamous cell carcinoma	>2026
volrustomig eVOLVE-Lung02	PD-1/CTLA-4 bispecific mAb		1L metastatic NSCLC	>2026
volrustomig eVOLVE-Meso	PD-1/CTLA-4 bispecific mAb		1L unresectable malignant pleural mesothelioma	>2026
CVRM				
<i>Andexxa</i>	anti-factor Xa reversal		acute major bleed	Launched
balcinrenone/dapagliflozin	MR modulator + SGLT2 inhibitor	<i>Farxiga</i> in the US; <i>Forxiga</i> in rest of world.	heart failure with CKD	>2026
baxdrostat BaxHTN	aldosterone synthase inhibitor		hypertension	H2 2025
baxdrostat/dapagliflozin	aldosterone synthase inhibitor and reversible inhibitor of SGLT2		CKD	>2026
<i>Wainua</i>	ligand-conjugated antisense	PP	patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)	Launched
zibotentan/dapagliflozin	endothelin A receptor antagonist/ SGLT2 inhibitor	dapagliflozin is marketed as <i>Farxiga</i> in the US; <i>Forxiga</i> in rest of world.	CKD with high proteinuria	>2026
Respiratory & Immunology				
<i>Fasenra</i> CALIMA SIROCCO ZONDA MIRACLE	IL-5R mAb	PP	severe uncontrolled asthma	Launched
<i>Saphnelo</i> TULIP 1 & TULIP 2 AZALEA (China)	type I IFN receptor mAb	PP	systemic lupus erythematosus	Launched
<i>Tezspire</i> NAVIGATOR DIRECTION (China)	TSLP mAb	PP	severe uncontrolled asthma	Launched
tozorakimab OBERON TITANIA PROSPERO MIRANDA	IL-33 mAb		chronic obstructive pulmonary disease	2026
tozorakimab TILIA	IL-33 mAb		severe viral lower respiratory tract disease	2026
Vaccines and Immune Therapies				
<i>Kavigale</i> (sipavibart) SUPERNOVA	SARS-CoV-2 LAAB		prevention of COVID-19	Approved
Rare Disease				
acoramidis	oral TTR stabiliser	PP	transthyretin amyloid cardiomyopathy	Submitted
ALXN2220 DepleTTR-CM	transthyretin depleter	PP	transthyretin amyloid cardiomyopathy	>2026
anselamimab	fibril-reactive mAb		amyloid light-chain amyloidosis	H2 2025

Development Pipeline *continued*

Phase III/Pivotal Phase II/Registration (listed until launched in all applicable major markets) *continued*

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
efzimfotase alfa	next generation TNSALP ERT		hypophosphatasia	2026
eneboparatide CALYPSO	parathyroid hormone receptor 1		hypoparathyroidism	H1 2025
gefurumab PREVAIL	humanised bispecific VHH antibody		generalised myasthenia gravis	H2 2025

Significant Life-cycle Management

Anticipated data timing and submission status is provided for assets in Phase III or beyond. Projects in Phase III unless otherwise noted.

Additional Information

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
Oncology				
Calquence + R-CHOP ESCALADE	BTK inhibitor + R-CHOP		1st-line diffuse large B-cell lymphoma	>2026
Calquence + venetoclax + obinutuzumab AMPLIFY	BTK inhibitor + BCL-2 inhibitor + anti-CD20 mAb		1st-line chronic lymphocytic leukaemia	Accepted
Calquence ECHO	BTK inhibitor	PP	1st-line mantle cell lymphoma	Launched
Calquence ELEVATE-TN ChangE (China)	BTK inhibitor	PP	1st-line chronic lymphocytic leukaemia	Launched
Datroway + Imfinzi AVANZAR	TROP2 ADC + PD-L1 + CTx	PP	non-squamous or non-squamous TROP2+ NSCLC 1L	H2 2025
Datroway TROPION-Breast02	TROP2 ADC	PP	1st-line triple negative breast cancer	H1 2025
Datroway +/- Imfinzi TROPION-Breast03	TROP2 ADC +/- PD-L1	PP	adjuvant residual disease triple negative breast cancer	2026
Datroway + Imfinzi TROPION-Breast04	TROP2 ADC +/- PD-L1	PP	neoadjuvant/adjuvant triple negative or HR-low/HER2-negative breast cancer	>2026
Datroway + Imfinzi TROPION-Breast05	TROP2 ADC + PD-L1	PP	1st-line triple negative breast cancer	2026
Datroway TROPION-Lung05	TROP2 ADC	PP	advanced or metastatic NSCLC with an EGFR mutation and progressed on prior systemic therapies, including TKIs and platinum-based chemotherapy	Accepted
Datroway + pembrolizumab TROPION-Lung07	TROP2 ADC	PP	1L NSCLC PD-L1 <50% non-squamous	2026
Datroway TROPION-Lung08	TROP2 ADC	PP	1L metastatic NSCLC without actionable genomic alterations and PD-L1 TPS ≥50%	2026
Datroway + rilvegostomig TROPION-Lung10	TROP2 ADC + PD-1/TIGIT bispecific mAb	PP	locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥50%) and without actionable genomic alterations	>2026
Datroway + rilvegostomig TROPION-Lung12	TROP2 ADC + PD-1/TIGIT bispecific mAb	PP	Stage I adenocarcinoma NSCLC who are ctDNA-positive or have high-risk pathological features	>2026
Datroway + Tagrisso TROPION-Lung14	TROP2 ADC + EGFR inhibitor	PP	1L EGFRm NSCLC	>2026
Datroway + Tagrisso TROPION-Lung15	TROP2 ADC + EGFR inhibitor	PP	2L advanced or metastatic EGFRm NSCLC	2026
Enhertu (platform) DESTINY-Breast07	HER2 targeting ADC	PP Phase II LCM	HER2+ breast cancer	
Enhertu + rilvegostomig DESTINY-BTC01	HER2 targeting ADC + PD-1/TIGIT bispecific mAb	PP	1L HER2+ biliary tract cancer	>2026
Enhertu DESTINY-Breast05	HER2 targeting ADC	PP	HER2+ post-neoadjuvant high-risk breast cancer	H2 2025
Enhertu DESTINY-Breast06	HER2 targeting ADC	PP	post-ET HER2-low and -ultralow/HR+ breast cancer 2L	Launched
Enhertu DESTINY-Breast09	HER2 targeting ADC	PP	1st-line HER2+ breast cancer	H2 2025
Enhertu DESTINY-Breast11	HER2 targeting ADC	PP	neoadjuvant HER2+ breast cancer	H1 2025
Enhertu DESTINY-Gastric04	HER2 targeting ADC	PP	2nd-line HER2+ gastric cancer	H2 2025
Enhertu DESTINY-Lung04	HER2 targeting ADC	PP	1st-line HER2m NSCLC	H2 2025

Development Pipeline *continued*

Significant Life-cycle Management *continued*

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
<i>Enhertu</i> DESTINY-PanTumor03 (China)	HER2 targeting ADC	PP Phase II LCM	HER2 expressing solid tumours	H2 2025
<i>Enhertu</i> DESTINY-PanTumour01	HER2 targeting ADC	PP Phase II LCM	HER2 mutant tumours	
<i>Enhertu</i> DESTINY-PanTumour02	HER2 targeting ADC	PP Phase II LCM	HER2 expressing solid tumours	Launched
<i>Imfinzi</i> (platform) BEGONIA	PD-L1 mAb with paclitaxel and multiple novel oncology therapies	Phase II LCM	1st-line metastatic triple negative breast cancer	
<i>Imfinzi</i> (platform) HUDSON	PD-L1 mAb + multiple novel oncology therapies	Phase II LCM	post IO NSCLC	
<i>Imfinzi</i> (platform) NeoCOAST-2	PD-L1 mAb + multiple novel oncology therapies	PP	NSCLC	
<i>Imfinzi</i> + CRT KUNLUN	PD-L1 mAb + CRT		locally advanced oesophageal squamous cell carcinoma	2026
<i>Imfinzi</i> + CRT PACIFIC-5 (China)	PD-L1 mAb + CRT	PP	locally-advanced (Stage III) NSCLC	Q3 2024
<i>Imfinzi</i> + CTx neoadjuvant AEGEAN	PD-L1 mAb + CTx		locally-advanced (Stage II-III) NSCLC	Launched
<i>Imfinzi</i> + CTx NIAGARA	PD-L1 mAb + CTx		muscle invasive bladder cancer	Submitted
<i>Imfinzi</i> + domvanalimab (AB154) PACIFIC-8	PD-L1 mAb + TIGIT	PP	unresectable Stage III NSCLC	>2026
<i>Imfinzi</i> + EV +/- <i>Imjudo</i> VOLGA	PD-L1 + nectin-4 targeting ADC +/- CTLA-4		muscle invasive bladder cancer	H2 2025
<i>Imfinzi</i> + FLOT MATTERHORN	PD-L1 mAb + CTx	PP	neoadjuvant/adjuvant gastric cancer	H2 2025
<i>Imfinzi</i> + <i>Imjudo</i> + SoC NILE	PL-L1 mAb + CTLA-4 mAb + SoC		1st-line urothelial cancer	H2 2025
<i>Imfinzi</i> + <i>Imjudo</i> + TACE +/- lenvatinib EMERALD-3	PD-L1 + CTLA-4 + VEGF +/- chemoembolisation		locoregional hepatocellular carcinoma	2026
<i>Imfinzi</i> + VEGF + TACE EMERALD-1	PD-L1 mAb + VEGF + TACE	PP	locoregional hepatocellular carcinoma	Q4 2023
<i>Imfinzi</i> + VEGF EMERALD-2	PD-L1 mAb + VEGF	PP	adjuvant hepatocellular carcinoma	2026
<i>Imfinzi</i> +/- <i>Imjudo</i> + CRT ADRIATIC	PD-L1 mAb +/- CTLA-4 mAb + CRT	PP	1st-line limited-stage SCLC	Launched
<i>Imfinzi</i> +/- <i>Imjudo</i> + CTx POSEIDON	PD-L1 mAb +/- CTLA-4 mAb + CTx		1st-line NSCLC	Launched
<i>Imfinzi</i> post-SBRT PACIFIC-4	PD-L1 mAb post-SBRT	PP	Stage I/II NSCLC	2026
<i>Imfinzi</i> POTOMAC	PD-L1 mAb		non-muscle invasive bladder cancer	H2 2025
<i>Lynparza</i> + abiraterone PROpel	PARP inhibitor + NHA	PP	prostate cancer	Launched
<i>Lynparza</i> + <i>Imfinzi</i> + bevacizumab DUO-O	PARP inhibitor + PD-L1 mAb + VEGF inhibitor	PP	1st-line ovarian cancer	Q2 2023
<i>Lynparza</i> + <i>Imfinzi</i> DUO-E	PARP inhibitor + PD-L1 mAb	PP	1st-line endometrial cancer	Launched
<i>Lynparza</i> MONO-OLA1	PARP inhibitor	PP	1st-line BRCAwt ovarian cancer	H1 2025
<i>Orpathys</i> + <i>Imfinzi</i> SAMETA	MET inhibitor + PD-L1 mAb	PP	1st-line papillary renal cell carcinoma	H2 2025
<i>Tagrisso</i> + <i>Orpathys</i> SAFFRON	EGFR inhibitor + MET inhibitor	PP	advanced EGFRm NSCLC	H2 2025
<i>Tagrisso</i> + <i>Orpathys</i> SAVANNAH	EGFR inhibitor + MET inhibitor	PP Phase II LCM	advanced EGFRm NSCLC	
<i>Tagrisso</i> +/- CTx neoadjuvant NeoADAURA	EGFR inhibitor +/- CTx		Stage II/III resectable EGFRm NSCLC	Q4 2024
<i>Tagrisso</i> ADAURA2	EGFR inhibitor		adjuvant EGFRm NSCLC Stage Ia2-Ia3 following complete tumour resection	>2026
<i>Tagrisso</i> LAURA	EGFR inhibitor		Stage III EGFRm NSCLC	Launched
<i>Tagrisso</i> ORCHARD platform study	EGFR inhibitor + multiple novel oncology therapies	PP Phase II LCM	2nd-line EGFRm osimertinib-resistant NSCLC	
<i>Truqap</i>	AKT inhibitor	Phase II LCM	prostate cancer	
<i>Truqap</i> + abiraterone CAPItello-281	AKT inhibitor + abiraterone		PTEN deficient metastatic hormone sensitive prostate cancer	Q4 2024

Development Pipeline *continued*

Significant Life-cycle Management *continued*

Compound	Mechanism	Additional Information	Area Under Investigation	Data readout/ submission status
<i>Truqap</i> + docetaxel CAPitello-280	AKT inhibitor + docetaxel		mCRPC prostate cancer	2026
<i>Truqap</i> + <i>Faslodex</i> + palbociclib CAPitello-292	AKT inhibitor + fulvestrant + CDK4/6 inhibitor	Phase Ib/III	1st-line triplet in early relapse/ET resistant locally advanced (inoperable) or metastatic breast cancer	>2026
CVRM				
<i>Wainua</i>	ligand-conjugated antisense	PP	patients with hereditary or wild-type transthyretin-mediated amyloid cardiomyopathy (ATTR CM)	2026
Respiratory & Immunology				
<i>Breztri/Trixeo</i> (PT010) KALOS LOGOS	LABA/LAMA/ICS	<i>Breztri</i> in Japan, China and the US. <i>Trixeo</i> in the EU.	asthma	H1 2025
<i>Breztri/Trixeo</i> ATHLOS	LABA/LAMA/ICS		COPD cardiopulmonary exercise test (CPET) trial	H2 2025
<i>Breztri/Trixeo</i> THARROS	LABA/LAMA/ICS	PP	cardiopulmonary outcomes trial in COPD	>2026
<i>Fasenra</i> MANDARA	IL-5R mAb		eosinophilic granulomatosis with polyangiitis	Launched
<i>Fasenra</i> NATRON	IL-5R mAb		hypereosinophilic syndrome	H1 2025
<i>Fasenra</i> RESOLUTE	IL-5R mAb	PP	chronic obstructive pulmonary disease	H2 2025
<i>Saphnelo</i> DAISY	type I IFN receptor mAb	PP	systemic sclerosis	2026
<i>Saphnelo</i> IRIS	type I IFN receptor mAb	PP	lupus nephritis	2026
<i>Saphnelo</i> JASMINE	type I IFN receptor mAb	PP	myositis	>2026
<i>Saphnelo</i> LAVENDER	type I IFN receptor mAb	PP	cutaneous lupus erythematosus	>2026
<i>Saphnelo</i> TULIP-SC	type I IFN receptor mAb	PP	systemic lupus erythematosus (subcutaneous)	H2 2025
<i>Tezspire</i> COURSE	TSLP mAb	PP Phase II LCM	chronic obstructive pulmonary disease	
<i>Tezspire</i> CROSSING	TSLP mAb	PP	eosinophilic oesophagitis	2026
<i>Tezspire</i> WAYPOINT	TSLP mAb	PP	nasal polyps	Q4 2024
Rare Disease				
<i>Koselugo</i> KOMET	MEK inhibitor	PP	neurofibromatosis type 1 adult	Submitted
<i>Ultomiris</i>	anti-complement C5 mAb		generalised myasthenia gravis	Launched
<i>Ultomiris</i>	anti-complement C5 mAb	Phase II LCM	proliferative lupus nephritis	
<i>Ultomiris</i>	anti-complement C5 mAb		haematopoietic stem cell transplant-associated thrombotic microangiopathy	H2 2025
<i>Ultomiris</i> ARTEMIS	anti-complement C5 mAb		cardiac surgery-associated acute kidney injury	2026
<i>Ultomiris</i> CHAMPION-NMOSD	anti-complement C5 mAb		neuromyelitis optica spectrum disorder	Launched
<i>Ultomiris</i> I CAN	anti-complement C5 mAb		immunoglobulin A nephropathy	>2026